Skip to main content
Top
Published in: Supportive Care in Cancer 11/2008

01-11-2008 | Short Communication

Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution

Authors: Nicla La Verde, Claudia Bareggi, Marina Garassino, Karen Borgonovo, Paola Sburlati, Donata Pedretti, Celso Bianchi, Silvia Perrone, Dorian Mihali, Stefano Cobelli, Cristina Mantica, Aurora Rizzo, Gabriella Farina

Published in: Supportive Care in Cancer | Issue 11/2008

Login to get access

Abstract

Goals of the work

Osteonecrosis of the jaw (ONJ) is a severe complication of bisphosphonates treatment. Bisphosphonates reduce skeletal adverse events and give a clinical benefit to cancer patients. Therefore, it is necessary to identify appropriate procedures to reduce ONJ injures by using a successful monitoring program. In a retrospective study we analyzed the impact of a prevention program based on clinical oral cavity examination, dentists, and patients’ education. The aim of the study was to evaluate if this approach might improve ONJ outcome in patients receiving pamidronate or zoledronate.

Materials and methods

We analyzed retrospectively two different groups of patients treated at our Institution: patients treated from October 2003 to June 2005 (group A) and patients treated from June 2005 to April 2007 (group B). In June 2005 the prevention program started for all our patients.

Main results

One hundred and eighty-six cancer patients with bone involvement, treated with bisphosphonates, were considered. Sixteen of them developed ONJ: eight before and eight after June 2005. We observed a consistent difference in the evolution of the two groups. In the first group, four patients underwent a major surgery (one partial maxillectomy, complicated by septic shock and oronasal communication; two partial mandibulectomies; and one segmental mandibular resection), with an important impairment of their quality of life; while the eight new ONJ cases, diagnosed after June 2005, were successfully treated without aggressive dental interventions, and achieved a good control of symptoms.

Conclusions

Bisphosphonates-related ONJ is a frequent adverse event (8.6%). The monitoring program proved very efficient to improve the clinical outcome of ONJ, avoiding an aggressive treatment and using a conservative approach and medical therapy.
Literature
2.
7.
go back to reference Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H et al (2007) Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 31(2):285–291PubMed Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H et al (2007) Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 31(2):285–291PubMed
9.
go back to reference Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104(1):83–93 doi:10.1002/cncr.21130 PubMedCrossRef Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104(1):83–93 doi:10.​1002/​cncr.​21130 PubMedCrossRef
13.
go back to reference Takeyama S, Shinoda H (2003) Pharmacological actions and pharmacokinetics of bisphosphonates. Clin Calcium 13:115–121PubMed Takeyama S, Shinoda H (2003) Pharmacological actions and pharmacokinetics of bisphosphonates. Clin Calcium 13:115–121PubMed
14.
go back to reference Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R et al (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62(2):148–152 doi:10.1016/j.critrevonc.2006.12.005 PubMedCrossRef Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R et al (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62(2):148–152 doi:10.​1016/​j.​critrevonc.​2006.​12.​005 PubMedCrossRef
15.
go back to reference Woo SK, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed Woo SK, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed
Metadata
Title
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution
Authors
Nicla La Verde
Claudia Bareggi
Marina Garassino
Karen Borgonovo
Paola Sburlati
Donata Pedretti
Celso Bianchi
Silvia Perrone
Dorian Mihali
Stefano Cobelli
Cristina Mantica
Aurora Rizzo
Gabriella Farina
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0484-3

Other articles of this Issue 11/2008

Supportive Care in Cancer 11/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine